Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $145M | $491M | $579M | $1.05B | $1.27B | $1.50B | $1.46B |
| Revenue growth | — | 237.5% | 17.8% | 81.4% | 20.7% | 18.5% | -2.8% |
| Operating income | -$39.5M | -$28.6M | -$129M | -$1.56B | -$168M | -$321M | -$270M |
| Operating margin | -27.2% | -5.8% | -22.3% | -148.7% | -13.3% | -21.4% | -18.5% |
| Net income | -$42.0M | -$31.4M | -$146M | -$270M | -$57.8M | -$136M | -$148M |
| Net margin | -28.8% | -6.4% | -25.3% | -25.7% | -4.6% | -9.1% | -10.1% |
| EPS (diluted) | — | — | — | -$6.50 | -$0.63 | -$54.06 | -$45.26 |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$28.3M | -$24.6M | -$51.1M | -$126M | -$76.0M | -$110M | -$91.2M |
| Capital expenditures | $1.45M | $2.93M | $3.29M | $2.23M | $1.83M | $0.00 | — |
| Free cash flow | -$29.7M | -$27.5M | -$54.4M | -$128M | -$77.9M | -$110M | — |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $32.6M | $36.3M | $5.30M | $17.5M | $36.3M | $38.8M | $25.0M |
| Total assets | — | $106M | $2.36B | $877M | $861M | $783M | $657M |
| Total liabilities | — | $146M | $300M | $354M | $427M | $634M | $797M |
| Long-term debt | — | $45.4M | $80.0M | $94.4M | $108M | $109M | $228M |
| Shareholders' equity | — | — | $274M | $5.85M | $142M | $75.9M | -$155M |
| Retained earnings | — | -$130M | -$39.4M | -$310M | -$367M | -$503M | -$651M |
| Shares (wtd avg diluted) | — | — | — | 41.6M | 295M | 2.94M | 3.27M |
Every figure is extracted from P3 Health Partners Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.